MONOPAR THERAPEUTICS INC (MNPR) Stock Price & Overview
NASDAQ:MNPR • US61023L2079
Current stock price
The current stock price of MNPR is 53.115 USD. Today MNPR is down by -2.9%. In the past month the price decreased by -0.92%. In the past year, price increased by 28.07%.
MNPR Key Statistics
- Market Cap
- 355.339M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.85
- Dividend Yield
- N/A
MNPR Stock Performance
MNPR Stock Chart
MNPR Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MNPR. When comparing the yearly performance of all stocks, MNPR is a bad performer in the overall market: 64.36% of all stocks are doing better.
MNPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNPR. No worries on liquidiy or solvency for MNPR as it has an excellent financial health rating, but there are worries on the profitability.
MNPR Earnings
MNPR Forecast & Estimates
20 analysts have analysed MNPR and the average price target is 115.04 USD. This implies a price increase of 116.59% is expected in the next year compared to the current price of 53.115.
MNPR Groups
Sector & Classification
MNPR Financial Highlights
Over the last trailing twelve months MNPR reported a non-GAAP Earnings per Share(EPS) of -1.85. The EPS increased by 55.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.75% | ||
| ROE | -9.95% | ||
| Debt/Equity | 0 |
MNPR Ownership
MNPR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.84 | 360.314B | ||
| AMGN | AMGEN INC | 15.1 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.51 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.86 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.01 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.6 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MNPR
Company Profile
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Company Info
IPO: 2019-12-19
MONOPAR THERAPEUTICS INC
1000 Skokie Blvd Ste 350
Wilmette ILLINOIS 60091 US
CEO: Chandler Robinson
Employees: 15
Phone: 18473880349
MONOPAR THERAPEUTICS INC / MNPR FAQ
What does MONOPAR THERAPEUTICS INC do?
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
What is the stock price of MONOPAR THERAPEUTICS INC today?
The current stock price of MNPR is 53.115 USD. The price decreased by -2.9% in the last trading session.
Does MONOPAR THERAPEUTICS INC pay dividends?
MNPR does not pay a dividend.
What is the ChartMill rating of MONOPAR THERAPEUTICS INC stock?
MNPR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of MONOPAR THERAPEUTICS INC (MNPR)?
MONOPAR THERAPEUTICS INC (MNPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.85).
What is the outstanding short interest for MONOPAR THERAPEUTICS INC?
The outstanding short interest for MONOPAR THERAPEUTICS INC (MNPR) is 33.02% of its float.